Divi’s Labs signs long-term supply deal with global pharma company

Divi’s Laboratories announced today that it has entered into a long-term manufacturing and supply agreement with a global pharmaceutical company. The agreement focuses on the manufacturing and supply of advanced intermediates, a crucial area for Divi’s Laboratories’ custom synthesis business.

According to a regulatory filing with the exchanges, the agreement is international in scope and is expected to contribute meaningfully to the company’s revenue. While the name of the partner and specific quantitative details remain confidential due to a confidentiality agreement, Divi’s Labs confirmed the agreement is a significant one.

To support the new partnership and future growth, Divi’s Laboratories plans to invest between ₹650 crore and ₹700 crore in capacity expansion at its existing manufacturing facilities. The investment will be funded through internal accruals.
The company stated that the agreement will benefit the customer through assured supply and will allow Divi’s Labs to further expand its presence in the custom synthesis market.